Nav: Home

Why are migraine patients skipping effective behavioral treatments?

June 05, 2018

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine.

Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred despite the fact that these treatments are considered first-line, safe and effective treatments by medical guidelines.

Those who were referred but did not seek treatment most commonly cited lack of time, cost concerns, and skepticism the treatments will work, according to the new study published in the June 5 issue of Pain Medicine.

An estimated 36 million Americans live with migraines, which are recurrent attacks that cause moderate to severe throbbing pain, and are often accompanied by nausea and/or vomiting and sensitivity to light and sound. Migraines are the sixth most disabling condition worldwide, often resulting in missed work and high utilization of health care services.

Previous research shows that behavioral migraine treatments, including cognitive behavioral therapy (CBT), stress management, relaxation techniques, and biofeedback -- learning to reduce muscle tension with help of a monitoring device -- may reduce symptoms by 50 percent or more. Behavioral treatments can be less costly than medications and have enduring benefits for migraine reduction, according to the researchers, which led them to explore why many patients were not following through on treatment.

"Migraines can be debilitating, so it stands to reason that many patients would want to access a treatment that reduces symptoms by half," says Mia Minen, MD, MPH, an assistant professor of Neurology and Population Health at NYU School of Medicine, and director of research for NYU Langone's Headache Division. "However, our research shows this is far from the case."

Researchers prospectively tracked 234 patients with migraines who presented to an academic headache center, and referred 69 of them for behavioral treatment with a therapist trained in migraines. Fifty-three patients who completed a follow-up interview within three months of their initial appointment were included in the analysis.

Of the patients referred for behavioral treatment, only 30 (56.6 percent) made an appointment. Researchers found no differences between those who started therapy and those who didn't when looking at age, gender, years of suffering from migraines and overall utilization of health care services. However, they did find a significant difference: people who had previously seen a psychologist were more likely to initiate therapy.

Of the patients who did not initiate behavioral treatment, half cited time limitations as a barrier to adherence. In addition to time, patients did not initiate for reasons including cost - since some insurance plans don't cover -- skepticism that it would work, contentment with their current treatment plan, and satisfaction that their headaches were already improving.

Dr. Minen and her colleagues say that more research is needed to develop new methods to overcome these barriers. They add that given concerns about migraine and stigma, research on whether stigma plays a role in limiting patients' abilities to access behavioral treatment should also be explored.

"As providers, we need to develop new ways to present evidence-based behavioral treatments to patients in a similar manner in which pharmacologic therapies are presented, with attention to how behavioral treatments can be part of a larger patient-centered care plan," she said.

Many drugs on the market that reduce or control migraine symptoms often can cause other negative symptoms, according to the authors. A new class of monoclonal antibody medications for migraine, called CGRP inhibitors, have generated excitement among the migraine community as a new treatment option. While these medications have been shown to result in a 50-percent reduction in half of those using them, they are not a cure for migraine; thus, there is a need for creating evidence-based scalable, accessible behavioral treatments, according to the authors.

Other available treatments for migraine include medications, vitamin supplements, and botulinum toxin injections.
-end-
This research received no grant funding support; Dr. Minen is a recipient of the American Academy of Neurology-American Brain Foundation Practice Research Training Fellowship, which provides salary support to conduct research.

In addition to Dr. Minen, researchers at NYU School of Medicine included Sarah Azarchi, BS, Rachel Sobolev, BA, Amanda Shallcross, ND, MPH, Audrey Halpern, MD, Thomas Berk, MD, and Naomi M. Simon, MD. Other researchers included Scott Powers, PhD, Richard B. Lipton, MD, and senior author Elizabeth Seng, PhD.

NYU Langone Health / NYU School of Medicine

Related Migraine Articles:

Migraine diagnoses positively associated with all-cause dementia
Several studies have recently focused on the association between migraine headaches and other headaches and dementia and found a positive migraine-dementia relationship.
New data indicate rise in opioid use for migraine treatment
An increasing number of Americans are using opioids to treat their migraine headaches, despite the fact that opioids are not the recommended first-line therapy for migraine in most cases.
Migraine increases the risk of complications during pregnancy and childbirth
Pregnant women with migraine have an increased risk of miscarriage, caesarean sections and giving birth to a child with low birth weight.
Food insecurity associated with migraine in young US adults
Food insecurity is when you worry that your food will run out before you have enough money to buy more.
Migraine neurobiology linked to prevalence in females
Low doses of a peptide known for decades to be involved in migraine trigger pain responses in female but not male rodents, according to a new research published in JNeurosci.
Is dry eye disease associated with migraine headaches?
Dry eye disease is when tears can't adequately lubricate the eyes and patients may feel a stinging, burning or scratchy sensation.
Pilot study: Migraine can be treated without medicine
By slightly changing the body's own molecules using a small inhaler, certain migraine patients can either cut down on medication or do without it completely.
Your brain with a migraine
When migraine sufferers see the tell-tale squiggly lines, light flashes and blind spots of a migraine aura, they prepare for a migraine.
86 million workdays lost to migraine in the UK every year
Migraine costs the UK economy £8.8 billion per year in lost productivity, a new report by the Work Foundation reveals.
When others fail, new migraine treatment may work
People who have tried unsuccessfully to prevent migraine with other treatments may find relief with a drug called erenumab, according to a preliminary study released today that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to 27, 2018.
More Migraine News and Migraine Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.